COVID-19 linked to brain complications in children hospitalised with virus

© iStock/oneblink-cj

Around one in 20 children hospitalised with COVID-19 develop related brain or nerve complications, a new study has shown.

Researchers at the University of Liverpool have identified a range of neurological complications in children that they suggest may be more common than in adults hospitalised with COVID-19.

The findings have been published in The Lancet Child and Adolescent Health.

The CoroNerve Studies Group, comprising a collaboration of academics from the universities of Liverpool, Newcastle, Southampton and UCL, developed a real-time, UK-wide notification system in partnership with the British Paediatric Neurology Association. The aim of the system was to investigate whether COVID-19 could cause nervous system complications in children.

From April 2020 to January 2021, researchers identified 52 cases of children less than 18 years old with neurological complications amongst 1,334 children hospitalised with COVID-19, giving an estimated prevalence of 3.8%. This compares to an estimated prevalence of 0.9% in adults admitted with COVID-19.

Ethnicity as a risk factor

Eight (15%) children presenting with neurological features did not have COVID-19 symptoms although the virus was detected by PCR, underscoring the importance of screening children with acute neurological disorders for the virus. Ethnicity was found to be a risk factor, with over two thirds of children being from a black or Asian background.

The research is the first to identify key differences between those with paediatric multisystem inflammatory syndrome (PIMS-TS) compared to those with non-PIMS-TS neurological complications. The 25 children (48%) diagnosed with PIMS-TS displayed multiple neurological features including encephalopathy, stroke, behavioural change, and hallucinations, making them more likely to require intensive care. Conversely, the non-PIMS-TS 27 (52%) children had a primary neurological disorder such as prolonged seizures, encephalitis (brain inflammation), Guillain-Barré syndrome, and psychosis. In almost half of these cases, this was a recognised post-infectious neuro-immune disorder, compared to just one child in the PIMS-TS group, suggesting that different immune mechanisms are at work.

Short-term outcomes were apparently good in two thirds (65%), although a third (33%) had some degree of disability and one child died at the time of follow-up. However, the impacts on the developing brain and longer-term consequences are not yet known.

First author Dr Stephen Ray, a Wellcome Trust clinical fellow and paediatrician at the University of Liverpool, said: “The risk of a child being admitted to hospital due to COVID-19 is small, but among those hospitalised, brain and nerve complications occur in almost 4%. Our nationwide study confirms that children with the novel post-infection hyper-inflammatory syndrome PIMS-TS can have brain and nerve problems; but we have also identified a wide spectrum of neurological disorders in children due to COVID-19 who didn’t have PIMS-TS. These were often due to the child’s immune response after COVID-19 infection.”

Follow-up research needed

Joint senior-author Dr Rachel Kneen, a Consultant Paediatric Neurologist at Alder Hey Children’s NHS Foundation Trust and honorary clinical Senior Lecturer at the University of Liverpool, said: “Many of the children identified were very unwell. Whilst they had a low risk of death, half needed intensive care support and a third had neurological disability identified. Many were given complex medication and treatments, often aimed at controlling their own immune system. We need to follow these children up to understand the impact in the long term.”

Joint senior-author Dr Benedict Michael, a senior clinician scientist and MRC Fellow at the University of Liverpool, said: “Now we appreciate the capacity for COVID-19 to cause a wide range of brain complications in those children who are hospitalised with this disease, with the potential to cause life-long disability, we desperately need research to understand the immune mechanisms which drive this. Most importantly- How do we identify those children at risk and how should we treat them to prevent lasting brain injury? We are so pleased that the UK government has funded our COVID-CNS study to understand exactly these questions so that we can help inform doctors to better recognise and treat these children.”


Subscribe to our newsletter


Please enter your comment!
Please enter your name here